Phase I-II Study of Crenolanib Combined With Standard Salvage Chemotherapy, and Crenolanib Combined With 5-Azacitidine in Acute Myeloid Leukemia Patients With FLT3 Activating Mutations

Trial Profile

Phase I-II Study of Crenolanib Combined With Standard Salvage Chemotherapy, and Crenolanib Combined With 5-Azacitidine in Acute Myeloid Leukemia Patients With FLT3 Activating Mutations

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2018

At a glance

  • Drugs Crenolanib (Primary) ; Azacitidine; Cytarabine; Etoposide; Fludarabine; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AROG Pharmaceuticals
  • Most Recent Events

    • 16 Jul 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2020.
    • 16 Jul 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2020.
    • 16 Jul 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top